In this video, health-care analyst David Williamson discusses how Big Pharma is attempting to catch up when it comes to creating a next-gen hepatitis-C cure. Today's news features a collaboration between Merck and Bristol-Myers Squibb. Has Big Pharma missed the boat, or is there still time to get on board with a winning combination? Watch and find out.
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Can it still make up ground with a winning hep-c drug cocktail?
David Williamson has no position in any stocks mentioned. Follow David on Twitter: @MotleyDavid.
The Motley Fool recommends Gilead Sciences, Johnson & Johnson, and Vertex Pharmaceuticals and owns shares of Johnson & Johnson. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned
Merck
MRK
$79.26
(-0.04%)
$0.03
Johnson & Johnson
JNJ
$149.81
(-0.61%)
$0.92
Gilead Sciences
GILD
$108.50
(0.46%)
$0.50
Bristol Myers Squibb
BMY
$46.87
(0.06%)
$0.03
AbbVie
ABBV
$185.16
(-0.18%)
$0.33
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles
2 High-Yield Healthcare Dividend Stocks to Buy Hand Over Fist in June
2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts
Should You Forget Medical Properties Trust and Buy These Unstoppable Dividend Stocks Instead?
Why Lilly's Bid for Verve Therapeutics Sent the Stock Soaring This Week
Is Oscar Health Stock Still a Buy?
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.